Patents by Inventor Laurent Courvoisier

Laurent Courvoisier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 10632119
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 28, 2020
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Fused Bicyclic 2,4-Diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor
    Publication number: 20190328735
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: October 26, 2018
    Publication date: October 31, 2019
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 10111872
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 30, 2018
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • FUSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK AND FAK INHIBITOR
    Publication number: 20170173017
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: March 7, 2017
    Publication date: June 22, 2017
    Inventors: Shawn P. Allwein, Laurent Courvoisier (deceased), Martin J. Jacobs, Gregory R. Ott
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 9623026
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 18, 2017
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • FUSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK AND FAK INHIBITOR
    Publication number: 20160243119
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: May 4, 2016
    Publication date: August 25, 2016
    Inventors: Shawn P. Allwein, Laurent Courvoisier (deceased), Martin J. Jacobs, Gregory R. Ott
  • Process for the preparation of and crystalline forms of optical enantiomers of modafinil
    Patent number: 9382200
    Abstract: The invention relates to a polymorphic form of (?)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 ?, and a process for the preparation thereof.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: July 5, 2016
    Assignee: Teva Sante
    Inventors: Olivier Neckebrock, Laurent Courvoisier, Stéphanie Graf, Gilles Serrure, Gérard Francois Coquerel, Sébastien Rose, Christine Besselievre, Franck Patrick Mallet, Adriaan Jan Van Langevelde
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 9339502
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: May 17, 2016
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Fused Bicyclic 2,4-diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor
    Publication number: 20150374693
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: August 12, 2015
    Publication date: December 31, 2015
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 9132128
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: September 15, 2015
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Fused Bicyclic 2,4-diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor
    Publication number: 20150011561
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: September 2, 2014
    Publication date: January 8, 2015
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Solid State Forms of 6-[4-[3-((R)-2-Methylpyrrolidine-1-yl)-propoxy]phenyl] 2H-pyridazine-3-one Hydrochloride
    Publication number: 20140275102
    Abstract: Solid state forms of the compound 6-[4-[3-((R)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2H-pyridazine-3-one hydrochloride (Compound 1), processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided. Compound 1 is a histamine H3 receptor antagonist/inverse agonist. Thus the provided solid state forms are useful, for example, for the manufacture of a medicament for the treatment of disorders mediated by the H3 receptor.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: CEPHALON, INC.
    Inventors: Stephen J. Bierlmaier, Laurent Courvoisier, Ralph C. Haltiwanger, Martin J. Jacobs
  • Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
    Patent number: 8759583
    Abstract: The invention relates to a method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form, comprising the steps of: a) contacting a pro-chiral sulphide of formula (II) with a metal chiral complex, a base and an oxidizing agent in an organic solvent; and optionally b) isolating the obtained sulphoxide of formula (I). wherein n, Y, R1, R1a, R2 and R2a are as defined in claim 1.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: June 24, 2014
    Assignee: Teva Sante
    Inventors: Laurent Courvoisier, Gerard Duret, Stephanie Graf, Laurence Prat-Lacondemine, Francois Rebiere, Nicolas Sabourault
  • Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
    Patent number: 8318979
    Abstract: The invention relates to a method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form, comprising the steps of: a) contacting a pro-chiral sulphide of formula (II) with a metal chiral complex, a base and an oxidizing agent in an organic solvent; and optionally b) isolating the obtained sulphoxide of formula (I). wherein n, Y, R1, R1a, R2 and R2a are as defined in claim 1.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: November 27, 2012
    Assignee: Cephalon France
    Inventors: Laurent Courvoisier, Veronique Courvoisier, legal representative, Gerard Duret, Stephanie Graf, Laurence Prat-Lacondemine, Francois Rebiere, Nicolas Sabourault
  • Novel forms of a multicyclic compound
    Publication number: 20120214998
    Abstract: The present invention provides alternative forms of Compound I, processes to reproducibly make them and methods of treating patients using them.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 23, 2012
    Applicant: Cephalon, Inc.
    Inventors: Stephen Bierlmaier, Michael Christie, Laurent Courvoisier, Veronique Courvoisier, R. Scott Field, R. Curtis Haltiwanger, Linli He, Martin J. Jacobs, Michael Kress, Robert E. McKean, Dale R. Mowrey, Joseph Petraitis, Mehran Yazdanian
  • Process for Enantioselective Synthesis of Single Enantiomers of Modafinil by Asymmetric Oxidation
    Publication number: 20120123161
    Abstract: The invention relates to a method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form, comprising the steps of: a) contacting a pro-chiral sulphide of formula (II) with a metal chiral complex, a base and an oxidizing agent in an organic solvent; and optionally b) isolating the obtained sulphoxide of formula (I). wherein n, Y, R1, R1a, R2 and R2a are as defined in claim 1.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 17, 2012
    Applicant: CEPHALON FRANCE
    Inventors: Laurent Courvoisier, Veronique Courvoisier, Gerard Duret, Stephanie Graf, Laurence Prat-Lacondemine, Francois Rebiere, Nicolas Sabourault
  • Novel Forms of a Fused Pyrrolocarbazole Compound
    Publication number: 20110230508
    Abstract: Alternative chemical and/or solid state forms of Compound I, processes to reproducibly make them and methods of treating patients using them.
    Type: Application
    Filed: May 11, 2011
    Publication date: September 22, 2011
    Applicant: CEPHALON, INC.
    Inventors: Stephen Bierlmaier, Laurent Courvoisier, Raymond Scott Field, R. Curtis Haltiwanger, Martin J. Jacobs, Robert E. McKean, Mehran Yazdanian, Veronique Courvoisier
  • Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
    Publication number: 20100048720
    Abstract: The invention relates to a polymorphic form of (?)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 14.14, 10.66, 7.80 and 4.02 ?, and a process for the preparation thereof.
    Type: Application
    Filed: July 22, 2009
    Publication date: February 25, 2010
    Applicant: Cephalon France
    Inventors: Olivier Neckebrock, Laurent Courvoisier, Stéphanie Graf, Gilles Serrure, Gérard Fransois Coquerel, Sébastien Rose, Christine Besselievre, Franck Patrick Mallet, Adriaan Jan Van Langevelde
  • Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
    Publication number: 20100048718
    Abstract: The invention relates to a polymorphic form of (?)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 5.23, 5.03, 4.22 and 4.10 ?, and a process for the preparation thereof.
    Type: Application
    Filed: July 22, 2009
    Publication date: February 25, 2010
    Applicant: Cephalon France
    Inventors: Olivier Neckebrock, Laurent Courvoisier, Stephanie Graf, Gilles Serrure, Gerard Francois Coquerel, Sebastien Rose, Christine Besselievre, Franck Patrick Mallet, Adriaan Jan Van Langevelde
  • Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
    Publication number: 20100048719
    Abstract: The invention relates to a polymorphic form of (?)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 12.31, 8.54, 7.27 and 3.62 ?, and a process for the preparation thereof.
    Type: Application
    Filed: July 22, 2009
    Publication date: February 25, 2010
    Applicant: Cephalon France
    Inventors: Olivier Neckebrock, Laurent Courvoisier, Stephanie Graf, Gilles Serrure, Gerard Francois Coquerel, Sebastien Rose, Christine Besselievre, Franck Patrick Mallet, Adriaan Jan Van Langevelde